Orbital lymphoma masquerading as panuveitis.
OBJECTIVE
To describe a case of orbital mucosa-associated lymphoid tissue (MALT) lymphoma masquerading as unilateral panuveitis.


METHODS
Retrospective chart review.


RESULTS
A 53-year-old female patient with unilateral vitritis and exudative retinal detachment refractory to immunosuppressive treatment was eventually diagnosed with orbital MALT lymphoma. Following treatment with radiotherapy and rituximab, the patient's intraocular inflammation and retinal detachment resolved.


CONCLUSIONS
Orbital MALT lymphoma can masquerade as refractory unilateral panuveitis with exudative retinal detachment and appears to respond to a combination of radiotherapy and specific B-cell-targeted systemic therapy.
Panda
Puneet
P
National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Forooghian
Farzin
F
Goodglick
Todd
T
Chan
Chi-Chao
CC
Nussenblatt
Robert
R
Sen
H Nida
HN
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D008875:Middle Aged; D009918:Orbital Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D015864:Panuveitis / Q000175:diagnosis* / Q000209:etiology; D018714:Radiotherapy, Adjuvant; D000069283:Rituximab; D041623:Tomography, Optical Coherence; D014057:Tomography, X-Ray Computed
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab